End-to-end solutions in the context of the biopharmaceutical industry are primarily based on single-use technologies, which allow for the greatest flexibility and agility.
Thanks to their versatility, these solutions are set to gain ever more importance and traction in the competitive race to develop new or produce tried-and-tested compounds and bring them to the market respectively to the patient.